• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Flu, encephalopathy, Japan

Anne

Senior Moderator
Influenza encephalopathy by pandemic (H1N1) 2009 virus
--------------------------------------
(1) Encephalopathy cases: week 28 to 45: 128 cases from 30 prefectures

Virus type: Pandemic (H1N1) 116 cases (88 percent), A type 15 cases,
B type 1 case
Ages: Under 15 years - 95.5 percent, median 8 years, range 1-67

(For comparison in weeks 1 to 27, there were 48 cases of encephalopathy)

(2) Total of acute influenza encephalopathy cases as a result of
pandemic (H1N1) influenza virus infection in Japan

60 reported cases as of 13 Nov 2009
Median: 8 years
Sex: male 35, female 25
25 cases had diseases before influenza infection

All 60 cases had disturbance of consciousness:
Days of beginning of onset of fever to disturbance of consciousness:
Median - 1 day
0 day - 12 cases
1 day - 36 cases
2 days - 8 cases
a single case - 3,4,7 & 8 days

Level by Japan Coma Scale (JCS):
Over 20 - 34 cases(GCS A-3)
10-19 - 9 cases(GCS A-4)
1-9 - 16 cases
unidentified -1 case

Period of disturbance of consciousness:
Unidentified - 2 cases
Over 48 hours - 19 cases
24-48 hours - 15 cases
Under 24 hours - 15 cases

Miscellaneous:
Cramps - 31 cases of 60 (52 percent)
Abnormal behaviors - 45 cases of 60 (75 percent)
Abnormal electroencephalogram - 35/47 (74 percent)
Brain CT - 23/56 (41 percent)
Brain MRI - 14/47 (30 percent)
No signals from electroencephalogram, CT and MRI - 8 cases

Treatment:
Tamiflu - 38/60 (63 percent)
Relenza - 13/60 (22 percent)
Both - 9/60 (15 percent)

Period of drug dose to disturbance of consciousness:
Median - 1 day
Before disturbance of consciousness - 12/60 (20 percent)
Same day - 38/60 (63 percent)
1 day - 10/60 (17 percent)

Brain low temp 6/60 (10 percent)
Blood plasma change 1/60 (2 percent)
Respirator 12/60 (20 percent)
None 13/60

Outcome:
Death - 3/59 (5 percent) (4.5.7 years)
After effects - 7/59 (12 percent)
Healing - 49/59 (83 percent)
Bed days in 50 cases - 2-39 days (median 9 days)

--
Communicated by:
Kunihiko Iizuka

[There was a report of cases of encephalitis and encephalopathy
following infection with the pandemic H1N1 influenza virus in the USA
earlier this year [2009]. The MMWR editorial note mentioned the
following: "Neurologic complications in children associated with
seasonal influenza have included acute cognitive and behavioral
problems, focal neurologic deficits, and death from neurologic
complications (4). Influenza-associated neurologic complications are
estimated to account for up to 5 percent of cases of acute childhood
encephalitis or encephalopathy (4) and were reported in 6 percent of
influenza-associated deaths among children during one influenza
season (2003-04) in the United States (5). The epidemiology of
influenza-associated encephalopathy has been described extensively in
Japan, where incidence has appeared to be higher than in other
countries (1). In Japan, approximately 80 percent of
influenza-associated encephalopathy cases occur in children aged less
than 5 years (1,6), and neurologic signs typically develop within 1-2
days of influenza symptom onset (1,6). Manifestations have included
seizures, altered consciousness, incoherence, irritability, and
psychotic behaviors (1,6). Outcomes reported in one case-series from
Japan ranged from complete resolution (in nearly 50 percent of
cases), to mild (20 percent) or severe neurologic sequelae (10
percent), to death (20 percent) (6). (See: Neurologic Complications
Associated with Novel Influenza A (H1N1) Virus Infection in Children
--- Dallas, Texas, May 2009. 24 Jul 2009. 58(28));773-778.
<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5828a2.htm>).

References from the MMWR article:
1.Morishima T, Togashi T, Yokota S, et al. Encephalitis and
encephalopathy associated with an influenza epidemic in Japan. Clin
Infect Dis 2002;35:512--7.
2.Maricich SM, Neul JL, Lotze TE, et al. Neurologic complications
associated with influenza A in children during the 2003--2004
influenza season in Houston, Texas. Pediatrics 2004;114:e626--33.
3.Dawood FS, Jain S, Finelli L, et al. Emergence of a novel
swine-origin influenza A (H1N1) virus in humans. N Engl J Med
2009;360:2605--15.
4.Amin R, Ford-Jones E, Richardson SE, et al. Acute childhood
encephalitis and encephalopathy associated with influenza: a
prospective 11-year review. Pediatr Infect Dis J 2008;27:390--5.
5.Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths
among children in the United States, 2003--2004. N Engl J Med
2005;353:2559--67.
6.Wada T, Morishima T, Okumura A, et al. Differences in clinical
manifestations of influenza-associated encephalopathy by age.
Microbiol Immunol 2009;53:83--8.
7.Ito Y, Ichiyama T, Kimura H, et al. Detection of influenza virus
RNA by reverse transcription-PCR and proinflammatory cytokines in
influenza-virus-associated encephalopathy. J Med Virol
1999;58:420--5. - Mod.MPP]





(For description of a genetic component in the
condition, see: Im Dev Med Child Neurol. 2009 Oct 7, Gika AD, Rich P,
Gupta S, Neilson DE, Clarke A. (Department of Paediatric Neurology,
St George's Hospital NHS Trust, London, UK.) - Mod.CP]






</pre>
 
Back
Top Bottom